Global Skin Cancer Diagnostics Industry Market Research 2022-2030

Some of the factors driving market growth include a higher incidence of skin cancer, extensive research and development projects, and increased awareness of skin cancer. Skin cancer is the most common form of cancer. Although most skin cancers are preventable, their incidence is increasing. People can recognize skin changes in the early stages of the disease. Risk factors include sunlight, sun lights and solariums, certain medical conditions or medications. Ultraviolet radiation changes the genetic material (DNA) of cells and is therefore the main cause of skin cancer. According to the American Cancer Society, sun exposure is the most preventable risk factor for all skin cancers.

 

According to the US Federal Centers for Disease Control and Prevention (CDC), the rate of new melanoma cases in men and women is increasing at an annual rate of 1.7% and 1.4%, respectively. Therefore, the increasing prevalence of skin cancer is increasing the growth of the studied market. However, a common side effect of radiation therapy is skin irritation on the treated body part. Skin reactions can range from mild redness and dryness (similar to sunburn) to severe peeling in some patients.

 

Most skin reactions to radiation therapy will disappear within a few weeks after the treatment is completed. In some cases, the treated skin will be darker than before and may still be more sensitive to sunlight. About two to three weeks after the first radiation treatment, the redness is obvious, and the irritation is similar to a sunburn. The skin may feel itchy, dry, red, or painful. There are also long-term side effects, such as skin color changes, lung problems, etc., which are the main constraints on the growth of the studied market.

 

Report scope:

 

 Ultraviolet rays are a major carcinogen, which can cause mutations caused by ultraviolet rays, loss of tumor suppressor gene activity, overexpression of keratinocyte oncogenes, and stimulate the development of skin malignant tumors. The skin cancer diagnosis and treatment market includes various diagnosis and treatment related to skin cancer.

 

Main market trends: 

 

Non-melanoma is expected to occupy a significant market share in cancer types. According to ASCO (American Society of Clinical Oncology) estimates, more than 3 million people in the United States are diagnosed with skin non-melanoma cancer each year. 

 

Basal cell carcinoma is more common than squamous Cell carcinoma is more common. About 80% of non-melanoma skin cancers are basal cell carcinomas. Similarly, CCS (Canadian Cancer Society) pointed out that non-melanoma skin cancer is the most common cancer diagnosed in Canadians. It accounts for at least 40% of all new cancer cases in Canada. The National Institutes of Health stated that in 2017, approximately 948 people in Japan died of non-melanoma skin cancer. Similarly, Australia also faces the burden of death caused by non-melanoma skin cancer. The Cancer Commission stated that between 2016-2027, approximately 679 people in Australia died from this cancer. In addition, the increasing burden of melanoma skin cancer is also expected to drive the market during the forecast period.

 

North America dominates the market and is expected to do so during the forecast period: 

 

North America is expected to dominate the market during the forecast period. According to the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma are the deadliest type of skin cancer and are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Therefore, the rising incidence of skin cancer in this region is an important factor driving the growth of the studied market. In addition, the latest advances in skin cancer treatment including photodynamic therapy (PDT) have been widely used to treat non-melanoma skin malignancies, thereby driving the growth of the research market during the prognosis period.

 

 Competitive landscape

 

 The global skin cancer diagnosis and treatment market is highly competitive and consists of several major players. Companies such as Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd. have a considerable share of the cancer treatment market. skin. .

 

Major Players

Sun Pharmaceutical Industries Ltd.
Amgen, Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Sun Pharmaceutical Industries Ltd.
 

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.